Compare · 7 comparisons
GLP-1 drugs, side by side
Each comparison is built only from the facts in our atlas: the molecule, the maker, what it acts on, how strong the evidence is, what the trials found, the known safety signals and what regulators allow. Every number links to its source.
These pages explain differences; they do not rank the drugs. Which one suits a person is a decision for them and their clinician.
Ozempic vs Wegovy
Ozempic and Wegovy are two brand names for the same medicine, semaglutide, and both are made by Novo Nordisk. What separates them is what each brand is approved to treat.
- Ozempic in the US
- Approved
- Wegovy in the US
- Approved
Ozempic vs Mounjaro
Ozempic contains semaglutide, made by Novo Nordisk. Mounjaro contains tirzepatide, made by Eli Lilly. Both brands are approved for type 2 diabetes. The core difference is in the molecule: semaglutide copies one gut hormone, tirzepatide copies two.
- Ozempic in the US
- Approved
- Mounjaro in the US
- Approved
Wegovy vs Zepbound
Wegovy contains semaglutide, made by Novo Nordisk. Zepbound contains tirzepatide, made by Eli Lilly. Both brands are approved in the US for chronic weight management. They differ in the molecule inside and in which hormone receptors it acts on.
- Wegovy in the US
- Approved
- Zepbound in the US
- Approved
Semaglutide vs Tirzepatide
Semaglutide and tirzepatide are both approved medicines built on the GLP-1 hormone. Semaglutide acts on the GLP-1 receptor only; tirzepatide acts on both the GIP and GLP-1 receptors. They come from different companies and are sold under different brand names.
- Semaglutide in the US
- Approved
- Tirzepatide in the US
- Approved
Tirzepatide vs Retatrutide
Both molecules come from Eli Lilly. Tirzepatide is an approved medicine. Retatrutide is still in clinical trials and is not approved by any regulator. Retatrutide adds a third target, the glucagon receptor, to the two that tirzepatide acts on.
- Tirzepatide in the US
- Approved
- Retatrutide in the US
- Prohibited
Semaglutide vs Liraglutide
Both are GLP-1 medicines from Novo Nordisk and both act on the same receptor. Liraglutide is the older of the two and is injected once a day; semaglutide lasts longer in the body and is given once a week, or as a daily tablet.
- Semaglutide in the US
- Approved
- Liraglutide in the US
- Generics available
CagriSema vs Tirzepatide
CagriSema combines two molecules in one weekly injection: cagrilintide, which copies the hormone amylin, and semaglutide. Tirzepatide is a single molecule that acts on the GIP and GLP-1 receptors. Tirzepatide is approved; CagriSema is not yet approved anywhere.
- CagriSema in the US
- Under review
- Tirzepatide in the US
- Approved